Introduction {#Sec1}
============

The decreasing fertility rate and increasing age of pregnant women make healthy pregnancy a top priority for global health^[@CR1],\ [@CR2]^. Exposure to teratogenic compounds during pregnancy can disrupt normal embryo development and cause early embryo death, growth retardation, or severe birth defects. Currently most companies still rely on *in vivo* animal tests for predicting potential teratogens, which have been considered as the regulatory gold standard for decades^[@CR3]^. However, due to large number of animals required and high inter-species variations in compound responses^[@CR4]^, these costly and time-consuming animal tests are usually performed at a very late stage of compound development in at least two species and the general concordance to human responses is not very satisfactory^[@CR5]^. Therefore, alternative *in vitro* human pluripotent stem cells (hPSCs)-based tests with reasonable accuracy should be developed and validated to establish regulatory standards^[@CR6]^.

Currently available hPSC-based models, together with those animal cell-based models, mainly focus on recapitulating temporal disruptions of cell proliferation and/or differentiation by teratogenic compounds using various molecular biomarkers such as proteins^[@CR7],\ [@CR8]^, genes^[@CR9]^, activity of specific signaling pathways^[@CR10]^ or metabolites^[@CR6]^. However, *in vivo* embryo development is a very complex process, which involves not only cell proliferation and differentiation, but also series of morphogenic movements spatially and temporally^[@CR11]--[@CR13]^. Disruption of cell proliferation and/or differentiation may only partially identify teratogenic effects of test compounds. Previously we have developed the first *in vitro* human development model mimicking spatiotemporally controlled mesoendoderm development using micropatterning, where both cell differentiation and cell migration were modeled and quantified^[@CR14]^. A confluent monolayer of circular hPSC colonies were patterned onto the tissue culture surface, and exposed to mesoendoderm induction medium for 3 days. Due to higher mechanical stress at the colony periphery compared with interior, cells at the periphery would differentiate into mesoendoderm cells^[@CR15]^ and migrate inwards to form a consistent mesoendoderm pattern on day 3^[@CR14]^. When dosing with paradigm teratogens, any disruptions on normal cell differentiation and collective cell migration could be captured by quantifying the morphology changes of the formed mesoendoderm patterns. A proof-of-concept testing using four known teratogens and one non-teratogen showed its improvement of teratogen detection compared to the mouse embryonic stem cell test (mEST).

In order to further develop this *in vitro* micropatterned hPSC (μP-hPSC) model for industrial applications, here we optimized and validated the assay with a group of 30 compounds. We acquired the cytotoxicity profile of each compound on both human embryonic cell line H9 cells and adult human dermal fibroblasts (aHDFs), and tested the dose response of each compound in the µP-hPSC colonies under mesoendoderm development. After acquiring the fluorescent images of mesoendoderm marker Brachyury (T) of the µP-hPSC colonies, we identified the most sensitive morphological features to reflect the major compound-induced mesoendoderm pattern changes. The lowest disruption concentration (LDC) of each compound was identified based on the reduced features. We also developed a two-step classification rule for the teratogen identification to establish the *in vivo* relevance of the compound screening in our micropatterned human pluripotent stem cell test (µP-hPST). This refined and validated assay with high predictability for teratogen detection would find wide applications in not only drug development but also as a cost-saving assay for early detection of teratogens in industrial chemicals, household and consumer goods, food and nutraceuticals, cosmetics and environmental toxins. This human cell-based *in vitro* assay will resolve the inter-species variation problems of the existing assays and contribute greatly to the reduction of animal uses.

Results {#Sec2}
=======

Cytotoxicity profile of test compounds {#Sec3}
--------------------------------------

A set of 30 compounds of known teratogenicity was selected to establish and validate the µP-hPST (Table [1](#Tab1){ref-type="table"}). The compounds include equal number of non-teratogens and teratogens, and differ in chemical property and therapeutic usage. Before tested in the µP-hPSC colonies, the cytotoxicity profile of each compound was acquired. Two cell lines, hPSC line H9 and adult human dermal fibroblast line aHDF, were tested to represent embryonic cytotoxicity and general cytotoxicity of the compound respectively (Supplementary Figs [S1](#MOESM1){ref-type="media"}, [S2](#MOESM1){ref-type="media"}). The IC~25~ values, which were the 25% inhibitory concentrations, were calculated as the highest non-cytotoxic concentrations of the compound (Table [2](#Tab2){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). Generally, compounds which were toxic at very low concentrations were mostly teratogens, such as Doxirubicin, 5-Fluorouracil, Sunitinib and Lovastatin (IC~25~ values \< 1 µg/ml); while compounds which showed minimum toxicity were mostly non-teratogens, such as Amoxicillin, Folic acid and Thiamine (IC~25~ values \> 800 µg/ml) (Fig. [1](#Fig1){ref-type="fig"}). Similarity in cytotoxicity profile could be found in compounds belonging to the same class of chemical property or therapeutic use, especially in terms of general cytotoxicity. Antineoplastic drugs (5-Fluorouracil, Diethylstilbestrol, Doxorubicin and tyrosine kinase inhibitors (TKIs)) showed general cytotoxicity at relatively low concentrations (IC~25aHDF~ \< 10 µg/ml) compared with other classes. Three of the four tested TKIs (Gefitinib, Imatinib and Sunitinib) exhibited higher general cytotoxicity than embryonic cytotoxicity, similar to antihypertensive compounds Methyldopa and Bosentan. Ethanolamine-based Histamine-1 antagonist Diphenhydramine and Doxylamine had similar general cytotoxicity (IC~25aHDF~ = 31.4 vs 45 µg/ml), but varied greatly in terms of embryonic cytotoxicity (IC~25H9~ = 2.4 vs 87 µg/ml). Loratadine, a piperidine Histamine H1 receptor antagonist, on the other hand, showed a much higher general cytotoxicity than Diphenhydramine and Doxylamine (IC~25aHDF~ = 3.2 µg/ml). While Vitamins Folic acid (Vitamin B9) and Thiamine (Vitamin B1) exhibited minimal toxicity to cells, Ascorbic acid (Vitamin C) showed toxicity at a much lower concentration and exhibited higher general cytotoxicity (IC~25aHDF~ = 63 µg/ml \< IC~25H9~ = 105 µg/ml). No obvious correlation was observed between compounds' teratogenicity potential and their higher embryonic cytotoxicity. There was similar number of compounds that had higher embryonic cytotoxicity than their general cytotoxicity in both non-teratogens and teratogens (5 VS 8, Fig. [1](#Fig1){ref-type="fig"}).Table 1Description of test compounds. The chemical properties and usages of drugs were found in PubChem Open Chemistry Database (<https://pubchem.ncbi.nlm.nih.gov>). NON: Non-teratogen, TER: Teratogen.Drug nameChemical propertyTherapeutic useFDA label*In vivo* teratogenicityAcetaminophenDerivative of acetanilideAnalgesic and antipyreticBNONAcyclovirNucleoside analog, DNA polymerase Inhibitor.Antiviral, to treat herpes labialis and genital herpesBNONAmoxicillinPenicillinAntibioticBNONAscorbic acidVitamin CTo treat or prevent vitamin C deficiencyANONCaffeineMethylxanthine, adenosine receptor antagonist, phosphodiesterase inhibitorCentral nervous system stimulant, anti-inflammatoryCNONDiphenhydramineEthanolamine-based Histamine-1 antihistamineAntiemetic, antitussive, anti-allergic, hypnotic and sedativeBNONDoxylamineEthanolamine-based Histamine-1 antihistamineTo treat allergy symptoms and insomnia; also used as an antitussive and antiemeticANONEsomeprazoleProton pump inhibitorAnti-ulcer, gastric acid secretion inhibitor and astrointestinal agentBNONFolic acidVitamin B9To treat or prevent folate deficiencies and megaloblastic anemiaANONIsoniazidSynthetic derivative of nicotinic acidAntitubercularCNONLoratadinePiperidine Histamine H1 receptor antagonistAntipruritic and anti-allergic, to treat allergic rhinitis and urticariaBNONMetoclopramideDopamine D2 antagonistGastroprokinetic and antiemeticBNONMethyldopaAdrenergic alpha2-AgonistAntihypertensiveBNONSitagliptinDipeptidyl peptidase 4 inhibitorHypoglycemic, to treat type 2 diabetesBNONThiamineVitamin B1To treat or prevent vitamin B1 deficiencyANON5-FluorouracilNucleoside metabolic inhibitorAntineoplasticDTERBosentanEndothelin receptor antagonistAntihypertensive, to treat pulmonary artery hypertensionXTERBusulfanAlkylating agentAnti-LeukemiaDTERCarbamazepineTricyclic compound chemically related to tricyclic antidepressants (TCA)Anticonvulsant and analgesicDTERDiethylstilbestrolNon-steroidal oestrogen hormoneAntineoplastic, to treat breast and prostate cancerXTERDiphenylhydantoinHydantoin derivativeAnticonvulsantDTERDoxorubicinAnthracycline topoisomerase inhibitorAntineoplasticDTERFurosemideSulfamoylanthranilic acid derivativeDiuretic; to treat hypertension and edemaCTERGefitinibTyrosine kinase inhibitor, EGFR inhibitorAntineoplastic, to treat lung cancerDTERImatinibTyrosine kinase inhibitor, inhibiting Bcr-Abl fusion protein tyrosine kinase, PDGFR and SCF/c-kitAnti-Leukemia and antineoplastic, to treat dermatofibrosarcoma protuberans and malignant gastrointestinal stromal tumorsDTERLovastatinHMG-CoA reductase inhibitorAnticholesteremicXTERMethimazoleThyroid hormone synthesis inhibitorAntithyroid, to treat hyperthyroidismDTERSunitinibTyrosine kinase inhibitor, inhibiting VEGFR2, PDGFRb, c-kit, and FLT3Antineoplastic, to treat gastrointestinal stromal tumor, pancreatic neuroendocrine tumor, and advanced renal cell carcinomaDTERVandetanibTyrosine kinase inhibitor, inhibiting VEGFR2 and EGFRAntineoplastic, to treat symptomatic or progressive medullary thyroid cancerDTERZiprasidoneBenzothiazolylpiperazine derivative; antagonist at the dopamine D2, serotonin 5-HT2A, 5-HT1A, 5-HT1D receptors;Antipsychotic, to treat Bipolar I disorder and SchizophreniaCTER Table 2Compound screening results in µP-hPST. The C~max~ values of each compound were mainly acquired from U.S. Food and Drug Administration website, European Medicines Agency website or published journals unless otherwise noted. The full list could be found in Supplementary Table [S1](#MOESM1){ref-type="media"}. NON: Non-teratogen, TER: Teratogen, NA: not applicable.Drug nameIC~25aHDF~ (µg/ml)IC~25H9~ (µg/ml)C~max~ (µg/ml)LDC (µg/ml)Step1: Is LDC \<= IC~25\ aHDF~ & IC~25H9?~Step 2: Is LDC \<= 10 C~max?~Teratogenicity in µP-hPSTTeratogenicity in other *in vitro* assays*In vivo* teratogenicityAcetaminophen4017124160N-NONNON^[@CR6]^NONAcyclovir2852675.6560YNNONNON^[@CR6],\ [@CR7]^NONAmoxicillin\>1000\>100014.4150YNNONNON^[@CR6]^NONAscorbic acid6310515680N---NONNON^[@CR6]^NONCaffeine12985.410130N---NONNON^[@CR6],\ [@CR7]^NONDiphenhydramine31.42.40.062.4YNNONNON^[@CR6]^NONDoxylamine45870.1245YNNONNON^[@CR6]^NONEsomeprazole42.138.91.6245N---NONNON^[@CR7]^NONFolic acid8948880.27900N---NONNON^[@CR6]^NONIsoniazid4883703.09500N---NONNON^[@CR6]^NONLoratadine3.2240.044N---NONNON^[@CR6]^NONMetoclopramide1541620.04120YNNONNON^[@CR6]^NONMethyldopa15.923.27.525N---NONNON^[@CR7]^NONSitagliptin77.13590.39\>360N---NONNON^[@CR6]^NONThiamine\>1000\>10000.111000YNNONNON^[@CR6]^NON5-Fluorouracil0.160.1548.40.025YYTERTER^[@CR6],\ [@CR7]^TERBosentan19.943.88.1716YYTERNON^[@CR6]^TERBusulfan19.20.51.220.2YYTERTER^[@CR6]^TERCarbamazepine28211110YYTERTER^[@CR6]^TERDiethylstilbestrol6.18.80.00565YNNONTER^[@CR7]^TERDiphenylhydantoin140562050YYTERNON^[@CR6]^TERDoxorubicin0.0030.00020.370.00015YYTERTER^[@CR7]^TERFurosemide3036240030YYTERNON^[@CR28]^TERGefitinib1.664.60.930.9YYTERTER^[@CR7]^TERImatinib2.719.51.560.75YYTERTER^[@CR7]^TERLovastatin0.680.300.010.01YYTERNON^[@CR6]^TERMethimazole\>10002520.31.5YYTERNATERSunitinib0.180.890.030.15YYTERTER^[@CR7]^TERVandetanib1.10.30.40.3YYTERTER^[@CR7]^TERZiprasidone2.714.40.21.25YYTERTER^[@CR7]^TER Figure 1Cytotoxicity profile of test compounds Red: teratogens, Black: non-teratogens.

The cytotoxicity of compounds may interfere with their teratogenic effects and disrupt the mesoendoderm pattern formation in µP-hPSC colonies. Therefore, the IC~25aHDF~ and IC~25H9~ values of each compound served as the cytotoxicity thresholds for teratogen testing and classification in our µP-hPST.

Dose-dependent mesoendoderm pattern disruptions by test compounds {#Sec4}
-----------------------------------------------------------------

The key test of the µP-hPST is to examine the morphological disruption effects of teratogenic compounds on µP-hPSC colonies during mesoendoderm formation. In normal mesoendoderm induction medium without compound exposure, cells at the periphery of the µP-hPSC colonies would always differentiate into T^+^ mesoendoderm cells and migrate inwards to form a consistent annular mesoendoderm pattern after 3 days of culture^[@CR14]^. Teratogen would affect the cell differentiation and/or migration process and change the morphology of the mesoendoderm patterns in a dose-dependent manner. To explore the teratogenic potential of test compounds, we selected 6 concentrations of each compound and tested them on the µP-hPSC colonies. The concentrations were selected to cover compound's cytotoxicity thresholds (IC~25aHDF~ and IC~25H9~) as well as its highest therapeutic concentration in human plasma (C~max~) (Table [2](#Tab2){ref-type="table"}, Supplementary Table. [S1](#MOESM1){ref-type="media"}). The µP-hPSC colonies were incubated in mesoendoderm induction medium together with the test compounds for 3 days. The medium was half changed every day. On day 3, all the colonies were fixed and immunostained for mesoendoderm marker T, the distribution of which indicated the morphology of the mesoendoderm patterns (Supplementary Fig. [S3](#MOESM1){ref-type="media"}).

From the T fluorescent images, we could see that most non-teratogens showed no obvious disruption effects compared with teratogens even at the highest dose except Acyclovir, Ascorbic acid, Diphenhydramine, Metoclopramide and Thiamine (Fig. [2b](#Fig2){ref-type="fig"}, Supplementary Fig. [S3a,b](#MOESM1){ref-type="media"}). Most teratogens, on the contrary, were observed with a clear dose-dependent response within the test range (Fig. [2b](#Fig2){ref-type="fig"}, Supplementary Fig. [S3c,d](#MOESM1){ref-type="media"}). Different disruption patterns could be identified from the images. The compounds could slow down or prevent mesoendoderm cell migration, for instance, in the case of Thiamine and Diphenylhydantoin; or promote cell migration, as in the case of Diethylstibestrol and Lovastatin. They could also decrease both cell differentiation and migration, as in the case of Carbamazepine; or promote both cell differentiation and migration, as in 5-Fluorouracil; or even promote mesoendoderm differentiation while decrease collective cell migration, as in Methimazole and Sunitinib. Beside teratogenicity, cytotoxicity effects could also affect mesoendoderm patterns. For example, under Busulfan treatment at concentrations higher than 0.5 μg/ml, which is its IC~25H9~ value, cell number in the µP-hPSC colonies decreased. Together with the compound's migration acceleration effects, much smaller and concentrated mesoendoderm patterns were observed (Supplementary Fig. [S3c](#MOESM1){ref-type="media"}). At concentration of 10 μg/ml, only a thin monolayer of cells remained within the colony and the mesoendoderm pattern was totally lost.Figure 2Morphological features showing the dose-dependent response of mesoendoderm pattern disruption. (**a**) The four features extracted from T fluorescent images. SD: Standard deviation; CV: Coefficient of variation. µ, µ′: Mean. (**b**) Representative T fluorescent images after drug treatment. Methyldopa: non-teratogen; Carbamazepine: teratogen. Scale bar, 200 µm. (**c**) Boxplots of the morphological features after Methyldopa and Carbamazepine treatment. Dose groups (1--6): 0, 7.5, 10, 15, 20, 25 μg/ml for Methyldopa, 0, 1, 10, 20, 25, 30 μg/ml for Carbamazepine. \**p* \< 0.01. The LDC for Methyldopa and Carbamazepine are 25 µg/ml and 10 µg/ml respectively.

Morphological feature selection to capture compounds' disruption effects {#Sec5}
------------------------------------------------------------------------

Since various morphological disruption patterns were acquired after compound treatment, a quantitative, multi-variate image characterization method was needed to measure the disruption effects and identify the lowest disruption concentration (LDC) of each compound. Initially we extracted 19 morphological features from each T fluorescent image to characterize the spatial distribution of the mesoendoderm cells. They were the typical statistical data descriptors such as sum (area), mean (position), variance, kurtosis, etc. Four features were related to skewness and entropy that did not correlate with compound treatment^[@CR14]^. Among the remaining 15 features, we clustered them into 7 morphological groups to quantify various compound disruptions. Plotting these compound disruption effects into box plots, we found that the high order statistical descriptors such as kurtosis and energy are less sensitive than the low order ones such as area, position, standard deviation (SD) and coefficient of variation (CV), in correlating with the compound-induced morphological changes at low concentrations. Therefore, only these four best morphological features were selected to quantitatively characterize the mesoendoderm patterns among groups (Fig. [2a](#Fig2){ref-type="fig"}).

To identify the LDC of a test compound, we plotted the values of these four features from all dose groups and compared with the untreated controls respectively using unpaired two sample t-tests (Fig. [2c](#Fig2){ref-type="fig"}, Supplementary Fig. [S4](#MOESM1){ref-type="media"}). A significant disruption was defined as *p* \< 0.01. The lowest concentration which showed a significant morphological disruption without a breaking point at higher concentrations in at least one of the four features would be defined as the LDC (Fig. [2c](#Fig2){ref-type="fig"}, Supplementary Fig. [S4](#MOESM1){ref-type="media"}).

Generation of a two-step teratogen classification method {#Sec6}
--------------------------------------------------------

After the LDC values of all test compounds were identified in µP-hPST (Table [2](#Tab2){ref-type="table"}), compound classification was performed. Since the cytotoxicity of compounds may also disrupt the mesoendoderm pattern formation, we first compared the LDC values with the IC~25~ values of aHDF and H9 cells. The LDC of teratogens should be no higher than their IC~25aHDF~ and IC~25H9~ values. Otherwise, the test compound could be classified as a non-teratogen. By using this rule, 9 of the 30 compounds would be classified as non-teratogens and the remaining 21 compounds would be classified as teratogens (Table [2](#Tab2){ref-type="table"}). All of the 9 non-teratogens were consistent with their *in vivo* classifications; however, 6 of the identified teratogens were misclassified. When comparing their LDC values with their respective C~max~ values, we found that the LDC values were much higher, indicating that the physiological relevance should also be taken into account. To achieve this, a second step of the classification was implemented to examine the *in vivo* relevance (Fig. [3](#Fig3){ref-type="fig"}). A threshold using a scale factor of C~max~ was applied. If the LDC of a test compound were higher than the scale factor of C~max~, which means this teratogenic effect was unlikely to happen clinically, we would classify the compound as a non-teratogen; otherwise, it be a teratogen (Fig. [3](#Fig3){ref-type="fig"}).Figure 3Two-step decision rule for teratogen classification.

To investigate the value of scale factor for C~max~, we had all 21 unclassified compounds tested using leave-one-out rule after Step 1^[@CR16],\ [@CR17]^. The LDC and C~max~ values of the compounds, together with their known teratogenicity class served as inputs to the model to find the optimal scale factor (Supplementary Table [S2](#MOESM1){ref-type="media"}). Results showed that a scale factor of 7--10 could achieve the best classification accuracy across all test runs (AUC \>= 96%) (Supplementary Fig. [S4](#MOESM1){ref-type="media"}), with only Diethylstilbestrol misclassified as false positive (Fig. [4](#Fig4){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). To verify such optimal scale factor, we also had LDC and C~max~ used as features and thus created a binary classification model using multinomial logistic regression (MLR) and support vector machine (SVM). The binary classification results (AUC = 91.7% for both MLR and SVM) were comparable to the scale factor based classification with only one compound being misclassified (Supplementary Fig. [S6](#MOESM1){ref-type="media"}) and thus proved that second step of proposed classification rule could recapitulate the inherent difference of the tested compounds.Figure 4Linear comparison results for the identification of best C~max~ scale factor. Only Diethylstilbestrol was misclassified as a non-teratogen when Step 2 of the classification rule was LDC \<= 7--10 fold of C~max~ for teratogens.

Assay performance {#Sec7}
-----------------

By extracting four morphological features to find LDC and a two-step classification method to classify the compounds, we could improve our µP-hPST assay to achieve 97% accuracy, 100% specificity and 93% sensitivity in screening 30 paradigm compounds (Table [3](#Tab3){ref-type="table"}). We compared our assay performance with the Targeted Biomarker Assay^[@CR6]^, which is one of the state-of-the-art hPSC-based teratogen screening models. The assay measures the ratio of two metabolites which are Ornithine and Cystine in hPSC maintenance culture to identify compound's disruption concentration, and compares it with *in vivo* C~max~ to classify the compound's teratogenicity^[@CR6]^. The µP-hPST captures the disruption of mesoendoderm patterns by affecting spatiotemporally controlled cell differentiation and migration, and exhibits better performance in terms of accuracy, sensitivity and specificity. It could correctly classify Bosentan, Diphenylhydantoin and Lovastatin, which were all misclassified in the Targeted Biomarker Assay (Table [3](#Tab3){ref-type="table"}). It can also correctly identify Furosemide as teratogen which was misclassified in mEST (Table [2](#Tab2){ref-type="table"}).Table 3Summary of the uP-hPST assay performance.AssayNo. of compoundsSensitivitySpecificityAccuracyµP-hPST3093%100%97%Targeted Biomarker Assay3679%100%89%

Discussion {#Sec8}
==========

Precise control of cell differentiation and migration patterns is critical during all stages of the embryo development^[@CR18]--[@CR21]^. Teratogens could disrupt embryo development through interfering cell differentiation and morphogenetic movements, resulting in various birth defects. Currently one of the most accurate and commonly used clinical examinations for teratogenicity is direct morphological observations using B-mode ultrasonography. For *in vitro* teratogen screenings, some studies have examined the morphological changes due to teratogenic disruptions in both cell differentiation and migration using animal embryos or cells, such as the rat whole embryo culture (rWEC) assay^[@CR22]^, the zebrafish embryo culture (ZEC) assay^[@CR23],\ [@CR24]^, and a newly developed assay using mouse embryoid body (mEB) by Marikawa's group^[@CR25],\ [@CR26]^. However, these assays are under performing (\~70--80% accuracy for the rWEC and ZEC assays)^[@CR27]^. We have established the first *in vitro* hPSC-based and fully quantitative morphometric assay which captured both cell differentiation and cell migration processes, and successfully eliminated inter-species variations^[@CR14]^. Refined and validated using 30 compounds, our µP-hPST exhibited the highest accuracy compared with other existing *in vitro* teratogen screening models using animal embryos and cells^[@CR8],\ [@CR10],\ [@CR22],\ [@CR24],\ [@CR27],\ [@CR28]^, or hPSCs^[@CR6],\ [@CR7]^.

The µP-hPST recapitulated the mesoendoderm formation process which occurs during gastrulation. One key reason is that the spatial and temporal control of primitive streak formation and mesoendoderm generation is critical in initiating the correct human body plan, which is followed by the three germ layer generation and organogenesis^[@CR29],\ [@CR30]^. By quantifying the morphological disruptions of the cell differentiation and collective cell migration patterns that are the two critical processes in every stage of the embryonic development, we could detect teratogens affecting not just mesoendoderm but also the other stages of embryo development. For example, the µP-hPST can detect the teratogenic effects of Diphenylhydantoin and Carbamazepine. Diphenylhydantoin is known to induce orofacial, limb, cardiovascular and neurobehavioral anomalies^[@CR6],\ [@CR31]^, and Carbamazepine could cause neural tube defects, cardiovascular and urinary tract anomalies, and cleft palate in newborns^[@CR32]^.

Dose-dependent response is a key feature of compounds' teratogenic effects. The identification of human teratogens always correlates with their clinical therapeutic dose. Therefore, it's crucial to compare the *in vitro* teratogenic concentration range with their *in vivo* therapeutic dose when screening teratogens *in vitro*. In this study, without comparing the *in vitro* LDC with the *in vivo* C~max~ of the test compounds, the assay would yield high false positive rate (6/21 = 28.6%). The second step of the classification approach was established based on an intuitive linear relationship assumption between LDC and C~max~, and verified using MLR and SVM binary classification models with comparable classification accuracy. After applying a second classification step which excluded compounds whose LDC was higher than 7--10 fold of C~max~, only one false negative result was observed. This two-step classification rule was also applicable to the five paradigm compounds tested previously^[@CR14]^, all the compounds (one known non-teratogen and four teratogens) could still be correctly classified (Supplementary Table [S3](#MOESM1){ref-type="media"}). For predictability of teratogen identification among unknown compounds, the two-step classification method has its unique advantages compared with the Targeted Biomarker Assay, which uses C~max~ as a reference for classification^[@CR6]^. For compounds with unknown C~max~, the µP-hPST can quickly identify candidates which are more likely non-teratogens by acquiring all negatives in Step 1 of the classification rule, and provide useful information regarding the potential *in vivo* teratogenic concentration range for those with uncertain teratogenicity.

The µP-hPST achieved 97% accuracy using the two-step classification method in the current teratogen screen of 30 compounds, among which the identified teratogens could affect different stages of embryonic development with different mechanisms of teratogenicity. However, considering the complexity of the teratogenic mechanisms, more teratogen screens using additional compounds are required to further test the predictability of our current assay. These compounds may include chemicals of different chemical classes and usages, or compounds which have differential teratogenic effects but share similar chemical structures.

Although *in vivo* animal assays have been used for teratogen screening for decades and are required by regulatory bodies, they cannot fully reproduce human responses due to high inter-species variations (\~40%)^[@CR5]^. False negatives generated by these *in vivo* animal models due to species variability have caused irreversible social tragedies such as the case of Thalidomide^[@CR33]^. An increase from testing one animal species to two could lower the chance of false negatives to \~12.5% (by keeping the 40% species variability consistent), but would significantly increase the false positive rate^[@CR5]^. Our µP-hPST is an *in vitro* hPSC-based assay which eliminates the inter-species variability, and has much better prediction accuracy (97% accuracy, 100% specificity and 93% sensitivity) compared with both *in vivo* animal models and other existing *in vitro* assays. However, it still cannot detect all teratogenic compounds possibly due to the inherent limitations shared by all *in vitro* assays (1 in 15 teratogens was classified as false negative). A combination of the µP-hPST with a second *in vivo* or *in vitro* assay may serve as an option for human teratogen detection. For compounds with existing animal testing data, the use of µP-hPST could eliminate potential false negatives by providing human-specific testing results. As for new compounds screening, the µP-hPST could be first applied to save costs and time, and comparing the negatives with further *in vivo* animal test. The µP-hPST could best serve as an early-phase teratogen screening assay for pharmaceutical companies and research institutions, or a late phase verification of animal testing results.

Conclusion {#Sec9}
==========

The µP-hPST is the first *in vitro* hPSC-based morphometric assay for human teratogen screening, which could capture compound's teratogenic effects in both cell differentiation and collective cell migration. It eliminated inter-species variations, and achieved 100% specificity, 93% sensitivity and 97% accuracy in 30 compound screen. The µP-hPST could serve as a good teratogen-screening assay independently or complementing other assays to reduce animal use, accelerate early discovery-phase drug screening, or general chemical screening.

Materials and Methods {#Sec10}
=====================

Compounds {#Sec11}
---------

All compounds used in this study were purchased from Selleck Chemicals or Sigma-Aldrich: 5-Fluorouracil (F6627,Sigma-Aldrich), Acetaminophen (A7085, Sigma-Aldrich), Acyclovir (S1807, Selleck Chemicals), Amoxicillin (S3015, Selleck Chemicals), Ascorbic acid (A5960, Sigma-Aldrich), Bosentan (S4220, Selleck Chemicals), Busulfan (B2635, Sigma-Aldrich), Caffeine (27600, Sigma-Aldrich), Carbamazepine (C8981, Sigma-Aldrich), Diethylstilbestrol (D4528, Sigma-Aldrich), Diphenhydramine (S1866, Selleck Chemicals), Diphenylhydantoin (D4007, Sigma-Aldrich), Doxorubicin (S1208, Selleck Chemicals), Doxylamine (D3775, Sigma-Aldrich), Esomeprazole (S1743, Selleck Chemicals), Folic acid (F7876, Sigma-Aldrich), Furosemide (F4381, Sigma-Aldrich), Gefitinib (S1025, Selleck Chemicals), Imatinib (S1026, Selleck Chemicals), Isoniazid (S1937, Selleck Chemicals), Loratadine (S1358, Selleck Chemicals), Lovastatin (S2061, Selleck Chemicals), Methimazole (S1609, Selleck Chemicals), Methyldopa (S1642, Selleck Chemicals), Metoclopramide (M0763, Sigma-Aldrich), Sitagliptin (S4002, Selleck Chemicals), Sunitinib (S1042, Selleck Chemicals), Vandetanib (S1046, Selleck Chemicals), Thiamine (T4625, Sigma-Aldrich), Ziprasidone (S1444, Selleck Chemicals).

All compounds were dissolved in DMSO (D2650, Sigma-Aldrich) except the following compounds, which were dissolved in culture medium: Acyclovir, Caffeine, Methimazole, Isoniazid, Folic acid and Thiamine.

Cell maintenance and differentiation {#Sec12}
------------------------------------

Human embryonic cell line H9 (WiCell Research Institute, Inc) and adult human dermal fibroblast (aHDF, Lonza) were cultured as previously described^[@CR14]^. Briefly, H9 cells were cultured in tissue culture plates coated with Matrigel^TM^ (354277, BD Biosciences) in mTeSR^TM^1 medium (05850, StemCell^TM^ Technologies). Dispase (07923, StemCell^TM^ Technologies) treatment and mechanical scraping were applied during normal subculture. The aHDF cells was cultured in DMEM medium (10569-010, Gibco), supplemented with 10% FBS (SV30160.03, Thermo Scientific Hyclone) and 1% Pen-Strep (09367-34, Nacalai Tesque). Cells were subcultured every 5--6 days using 0.25% Trypsion-EDTA (25200-114, Gibco) to detach the cells.

To induce mesoendodermal differentiation, H9 cells were cultured in serum-free STEMdiff^TM^ APEL^TM^ medium (05210, StemCell^TM^ Technologies) supplemented with 100 ng/ml Activin A (338-AC-025, R&D Systems), 25 ng/ml BMP4 (314-BP-010, R&D Systems) and 10 ng/ml FGF2 (233-FB-025, R&D Systems). For compound testing in the μP-hPST, the final concentration of DMSO in the medium was lower than 0.5%.

Cytotoxicity assay {#Sec13}
------------------

The adverse effect of test compounds on cell proliferation and viability was detected using CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS, G3580, Promega). 10,000 H9 cells or 500 aHDF cells were seeded in 96-well tissue culture plates. For H9 cells, Matrigel^TM^ was coated before seeding. For each compound, 8 concentrations from serial 5-fold dilutions were tested besides the vehicle controls. Cells were cultured for 3 days with medium half change every day before cell viability was measured. Each drug was tested in three independent runs and its IC~25~ values (inhibitory concentrations which can cause 25% of reduction in cell number) were acquired by logistic regression using OriginPro 9.

Generation of μP-hPSC colonies {#Sec14}
------------------------------

The polydimethylsiloxane (PDMS) stencil was fabricated as previously described^[@CR14]^. Circular patterns with 1 mm in diameter were generated on each stencil, which is in square shape and fit for 60-mm dishes. To generate μP-hPSC colonies, autoclaved PDMS stencils were sealed onto tissue culture dishes using 70% ethanol, and coated with 300 μl Matrigel^TM^ diluted in DMEM/F12 (11330032, GIBCO) for 5 hr at 37 °C. For cell seeding, single cells were acquired using Accutase (SCR005, Merck Millipore), and seeded at 5190 cells/mm^2^ in cell maintenance medium containing 10 μM Y27632 (688000, Calbiochem, Merck Millipore). After 45 min, stencils were peeled off and the surface was treated with 0.5% Pluronic F-127 (P2443, Sigma-Aldrich) in DMEM/F12 for passivation. Cells were incubated for at least 3 hr in Y27632-containing medium before switched to normal mTeSR^TM^1 medium. Differentiation started the next day.

Immunofluorescence staining and microscopy {#Sec15}
------------------------------------------

On day 3 of differentiation, cells were fixed using 4% paraformaldehyde for immunofluorescence staining of mesoendoderm marker Brachyury (T). Cells were permeabilized with 0.5% Triton X-100 in 1X PBS and incubated in 2% BSA in 0.1% PBS Triton X-100 for 3 hr at room temperature (RT). Cells were incubated overnight with goat anti-Brachyury (AF2085, R&D Systems) primary antibody (1:100) at 4 °C and then incubated in Alexa Fluor^®^ 546 donkey anti-goat IgG (A11056, Life Technologies) secondary antibody (1:1000) for 1 hr at RT after washing. Fluorescence imaging was done using Olympus IX81 epifluorescence microscope (Olympus, Japan).

Morphological feature extraction {#Sec16}
--------------------------------

Image analysis was performed using Matlab Image Processing Toolbox and Statistical Toolbox (Mathworks). The µP-hPSC colonies were identified using intensity differences from background. Segmentation using Otsu's method was performed to identify T^+^ regions of the colonies. Four morphologic features including Area, Position, Standard deviation (SD) and Coefficient of variation (CV) of the T^+^ region were calculated to represent the morphological distribution of the mesoendoderm patterns.

Classification model {#Sec17}
--------------------

All the classification analysis was done using Matlab Statistical Toolbox (Mathworks). To identify the best scale factor of C~max~ for drug classification, linear comparison was performed using LDC and C~max~ values. The leave-one-out cross validation rule was applied. For each run, a factor ranging from 1 to 20 was tested with an interval of 1. Best parameters were then chosen based on the highest area under the receiver operating characteristic curve (AUC) values acquired in respective Receiver Operating Curve (ROC) evaluation. Multinomial logistic regression (MLR) and support vector machine (SVM) using leave-one-out cross validation approach were further utilized to verify the classification accuracy of linear comparison using LDC and C~max~ as input features. The performances were evaluated using their respective AUC values.

Statistical analysis {#Sec18}
--------------------

The statistical analysis was done in R (Version 3.1.2). Unpaired two-sample t-test was performed to evaluate statistical differences between compound-treated groups and control group. Differences were deemed as significant if *p* \< 0.01. The first dose showing significant disruptions without breakpoint in the following higher concentrations will be determined as the LDC of test compound.
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